In April 1986, we became involved in a clinical trial of an untested approach to enzyme replacement therapy for ADA deficiency in a gravely ill child with SCID who had unsuccessful haploidentical bone marrow transplantation and enzyme replacement by red cell transfusion (1). The new method, which involved injecting PEG-ADA, was based on the discovery that covalent attachment of PEG could prolong the circulating life and reduce the immunogenicity of proteins (2-4). The approach offered the possibility of achieving very high levels of plasma ADA activity and appeared to be feasible because, as discussed elsewhere (5, 6), efficient catabolism of extracellular ADA substrates can prevent their toxicity to ADAdeficient lymphoid cells. Detailed study of the initial patient and another provided information about the pharmacokinetics of PEG-ADA and suggested that weekly injections could be effective in correcting metabolic abnormalities and restoring a degree of immune function (1). An international clinical trial followed in which we monitored the biochemical and metabolic effects of PEG-ADA and the evolution of anti-ADA antibodies, in collaboration with the physicians and immunologists who cared for affected patients and evaluated their clinical status and immunologic function. Results with several patients treated with PEG-ADA for periods of less than 1 y have been published (l,7-9) , and the experience with 14 patients begun on treatment through the spring of 1990, when PEG-ADA (Adagen, Enzon, Inc., So. Plainfield, NJ) was approved by the US Food and Drug Administration, has been summarized (6). The IgG antibody response to PEG-ADA in 17 patients has been reported (10). The following is a brief summary of the current status of PEG-ADA therapy, with some new recommendations for its use, based on observations of 29 patients treated to date.
In addition to summarizing the overall experience with PEG-ADA, we describe the recovery of specific immune function during 1.5 to almost 4 y of enzyme replacement in three patients, who represent examples of ADA deficiency with early, delayed, and late onset of immunodeficiency disease. Two of these patients have become the first subjects of a "gene therapyn experiment begun at the National Institutes of Health in the fall of 1990. During their participation in this experiment, both children have continued to receive PEG-ADA without interruption. In evaluating treatment with both modalities simultaneously, it is informative to review their response to enzyme replacement alone.
RESULTS
Overview of PEG-ADA Therapy. Profile ofpatients treated with PEG-ADA. Through January 1992,29 patients had been treated with PEG-ADA. Overall, 15 patients began treatment at c 1 y, six at 1 to 2 y, and eight at 3 to 14 y of age. However, the age distribution changed as the study progressed, reflecting the fact that most of the initial group of patients had been diagnosed before PEG-ADA was available. Thus, during the 48 mo before March 1990 (when Food and Drug Administration approval was obtained), only two of 13 patients began treatment at <1 y of age, compared with 13 of 16 during the ensuing 2 1-mo period. At present, 18 patients have been under treatment for 16 to 7 1 mo (mean, 40 mo), the remainder from 1 to 1 1 mo.
None of the patients had an HLA-identical sibling. Only the have had uncomplicated chickenpox, after which they developed normal and persisting anti-varicella antibody titers (see below). We have also documented persisting normal anti-varicella titers in two older patients who had chickenpox while undergoing erythrocyte transfusion therapy several years before starting PEG-ADA (Rubinstein A, Chaffee S, unpublished data). Mortality. There have been two deaths in patients undergoing treatment with PEG-ADA. A critically ill infant who was respiratordependent died within a week of starting PEG-ADA (Souillet G, unpublished data). The second child developed severe autoimmune hemolytic anemia after an adenovirus infection during the 2nd month of treatment, which required immunosuppression with highdose prednisone and azathioprine; the child did not respond and succumbed to hemolysis and Candida sepsis in the 4th mo of treatment (Junker A, unpublished data).
CASE REPORTS OF THREE PATIENTS
Presentation. The three patients are referred to by the order in which they started treatment with PEG-ADA. PEG-ADA patient no. 5 (late onset, mild phenotype), now 10.6 y old, had no serious infections until age 3 y and was not diagnosed until age 5. Her history and first 6 mo of PEG-ADA treatment, begun in April 1987 at age 5.8 y, have been reported (7). In January 1991, at age 9.5 y, she became the second patient enrolled in the National Institutes of Health T-cell gene transfer experiment. Her current dose of PEG-ADA is 30 U/kg once a week.
PEG-ADA patient no. 9 (delayed onset), now 5.3 y old, was diagnosed with ADA deficiency and SCID at age 2 y during an evaluation for cough of several weeks duration. She had a history of recurrent nasal congestion and cough from age 3 mo, three episodes of otitis media, and one episode of pneumonia at 1 y of age. However, she had never been hospitalized. Treatment with PEG-ADA began in November 1988 when she was 2.2 y old. In September 1990, at age 4.0 y, she became the first subject of experimental gene therapy. Her current dose of PEG-ADA is 26 U/kg once a week.
PEG-ADA patient no. 14 (typical early onset, severe presentation), now 2.4 y old, was diagnosed with ADA deficiency and SCID at age 7 mo. She had a history of recurrent pneumonia, oral candidiasis, vomiting, chronic diarrhea, and failure to thrive from age 2 mo (16). She began treatment with PEG-ADA in April 1990 at age 8 mo (current dose, 30 U/kg once a week).
Correction of metabolic abnormalities. Trough plasma ADA activity in patients 5, 9, and 14 have averaged 22.4 + 6.7, 32.9 * 8.0, and 26.7 + 5.8 nmol/h/mL, respectively. Before treatment, erythrocyte dAdo nucleotide levels were 204,3 15, and 499 nmol/mL in patients 5, 9, and 14, respectively. With treatment, these levels have fallen to 3-9 nmol/mL (normal, <2). Erythrocyte SAHase activity in the three patients has increased from pretreatment values of 0.18-0.23 nmol/h/mg protein to >3 nmol/h/mg (normal, 4.2 + 1.9 nmol/h/mg).
Immune reconstitution. Patients 9 (Fig. 1 ) and 14 developed a prominent thymic shadow by the 3rd mo of treatment with PEG-ADA. In all three patients, lymphocyte counts increased sharply during the first 6-8 mo of treatment, then declined during the next 6-12 mo (shown for patients 5 and 9 in Fig. 24 and B) . In patient 5, T cells remained in a low normal range, whereas in patient 9 CD4 counts fell to -200; patient 14 had CD4 counts in the 400-600 range between 12 and 16 mo of treatment (not shown). In vitro lymphocyte responses to mitogens normalized by 3 mo in patients 5 and 9 ( Fig. 2C and D ) and by 6 mo in patient 14 (not shown) and have remained normal thereafter.
All three patients have shown significant in vitro responses to various antigens, including tetanus and Candida. In patients 5 and 9, the in vitro lymphocyte response to streptokinase antigen was followed serially; it developed between 6 mo and 1 y of treatment and persisted through the time gene transfer studies were begun (Fig. 2E and F) .
All three children developed normal Ig levels and specific antibody responses while on treatment with PEG-ADA alone. At 5 mo after starting therapy, patient 5 showed a normal antibody response to immunization with 4X 174, with amplification on rechallenge and IgM-to-IgG class switching (14). After immunization, she developed protective antibody titers against Haemophilus and antibody levels of >2000 ng/mL and 678 ng/ mL against pneumococcal serotypes 3 and 7, respectively (antibodies to these polysaccharide antigens were undetectable before treatment). She had a normal antibody response after varicella infection, which was maintained through the time that treatments with transfected T cells began (Fig. 3) . Patient 5 had antiblood group B titers of 1:8 in her 3rd y of treatment with PEG-ADA and of 1:5 12 afler 7 mo of combined treatment with PEG-ADA and gene-transfected T cells. Patient 9 lacked isohemagglutinins at age 2 y, before treatment, but developed a normal anti-A titer of 1:32 during her 1st y on PEG-ADA. After 10 mo of combined treatment, the titer had increased by two tubes to 1: 128. As noted above, patient 9 developed autoimmune thrombocytopenia afler a viral infection during her 2nd mo of PEG-ADA therapy. This resolved after several months of treatment with highdose IVIG (1 5). Patient 14 developed normal antibody and delayed-type hypersensitivity responses to immunization and to ordinary childhood infections during the period from 15 to 28 mo of age (7 to 20 mo of PEG-ADA therapy); she has also developed normal isohemagglutinin titers (Table 1, Fig. 3) .
Clinical improvement. All three patients were discharged from hospital shortly after initiation of PEG-ADA treatment and have since lived at home without medical restrictions on their social interaction. After 3 to 11 mo of PEG-ADA therapy, IVIG was discontinued in each case. In each, the Frequency of respiratory infections and diarrhea decreased markedly. Growth improved in all three., most dramatically in patient 9: her weight increased from below the 10th to above the 90th percentile, and her height increased from below the 5th to above the 25th percentile over an 18-mo period. The clinical improvement in all three patients after starting PEG-ADA therapy was gratifying and in all cases was sustained.
Patients 5 and 14 each contracted chickenpox at 7 mo of treatment, and patient 14 also had a 48-h episode of Coxsackievirus B hepatitis about 1 y after starting therapy. In each case, the illness was uncomplicated. Normal anti-varicella and antiCoxsackievirus B antibody levels appeared after these infections and have persisted (Fig. 3, Table 1 ). Patient 5 began school at ape 6. 5 mo after startine PEG-ADA. and has attended school . d > regularly since then (as Gas patient 9 since attaining school age in 1991).
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DISCUSSION
Enzyme replacement with PEG-ADA has proved to be a safer and more effective way of treating ADA deficiency than red cell transfusion. Although the circulating life of ADA in transfused red cells is longer than that of PEG-ADA, the ADA activity of 2.5 mL of the clinical preparation of PEG-ADA (Adagen) is equivalent to that of 4.5 L of erythrocytes. Far higher levels of circulating ADA activity can therefore be maintained by weekly or biweekly intramuscular injection of PEG-ADA than by 
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fetal development may cause a degree of irreversible damage that reduces the potential for normal lymphoid differentiation by the time treatment is begun after diagnosis. As discussed by Hirschhorn (in this supplement issue), the severity of the immune deficit in untreated patients with ADA deficiency correlates with the level of erythrocyte dATP, which reflects residual total body ADA activity. This implies that specific ADA gene mutations may in part determine clinical severity and response to enzyme replacement. That this may be the case is suggested by the recent finding that one patient with a very early clinical presentation A large number of patients will therefore have to be studied to establish the relationship between genotype and phenotype. To this end, we are analyzing ADA gene mutations in PEG-ADAtreated patients and characterizing the residual activity of the products of subcloned mutant enzymes. The preferred treatment for ADA deficiency remains transplantation of bone marrow from an HLA-identical sibling. When a matched donor is not available, PEG-ADA and HLA-haploidentical bone marrow transplantation are potentially effective but probably incompatible alternatives (improving recipient immune function with PEG-ADA might enhance the chances of graft rejection). Some immunologists feel that haploidentical transplantation should always be performed before resorting to enzyme replacement, because the procedure is potentially curative. However, only the first of 29 patients had undergone unsuccessful haploidentical bone marrow transplantation before receiving PEG-ADA. The reasons for choosing PEG-ADA as primary therapy have varied, but a major factor has been the significant morbidity and mortality of haploidentical transplantation, particularly when camed out using preconditioning with 1 cytotoxic drugs (18, 19) . A 1990 review of the European experience reported a 2-y posttransplant survival rate of 53% in 19 1 ADAdeficient SCID patients treated with haploidentical marrow 1 (19). In contrast, only two deaths have occurred among PEG-ADA-treated patients. The difference in mortality is more impressive when it is appreciated that several PEG-ADA-treited patients had severe viral or Pneumocystis carinii pneumonia and were considered too ill to undergo marrow transplantation. There have been no clinically significant adverse reactions to PEG-ADA, whereas graft versus host disease is potentially a serious 1 complication of bone marrow transplantation.
A form of gene therapy is currently under investigation at the National Institutes of Health (reviewed by Blaese in this issue). The gene treatment involves repeated infusions of activated, IL-2-dependent patient T cells that have been exposed in vitro to an ADA cDNA-bearing retroviral vector. PEG-ADA therapy is required to provide sufficient mature patient T cells for gene transfer to be performed. Whether, after repeated cycles, the level of circulating ADA activity provided by infusion of gene-transfected T cells will be sufficient to sustain the survival and function of the patient's ADAdeficient T cells in the absence of ongoing may b W small. There may decrease to very, very low levels, and yet they do not develop be a very fine line.
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